# Biotech Daily Digest ‚Äî 2025-10-23

**40 items from 3 sources**

## Summary by Source

- Endpoints News: 9 items
- Fierce Biotech: 9 items
- arXiv q-bio: 22 items


## Endpoints News

- **[Ventyx's stock soars on cardiovascular data for NLRP3 drug](https://endpoints.news/ventyxs-stock-soars-on-cardiovascular-data-for-nlrp3-drug/)**  
  _Thu, 23 Oct 2025 14:31:10 +0000_  
  Ventyx Biosciences' Phase 2 data showed a significant reduction in cardiovascular risks in patients with obesity through NLRP3 inhibition, a closely watched target in neurologic and cardiometabolic drug development.

 After the readout was

- **[Are recent strides in neurology R&D enough to make it a hot M&A target?](https://endpoints.news/are-recent-strides-in-neurology-rd-enough-to-make-it-a-hot-ma-target/)**  
  _Thu, 23 Oct 2025 14:00:48 +0000_  
  Neurology has long been seen as a high-risk investment.

 Biopharma‚Äôs understanding of how the brain works is still rudimentary compared with that of other organs, as is its knowledge of what drives specific neurological diseases ...

- **[Drug launch prices spiked from 2022 to 2024, new ICER report finds](https://endpoints.news/drug-launch-prices-spiked-from-2022-to-2024-new-icer-report-finds/)**  
  _Thu, 23 Oct 2025 12:00:38 +0000_  
  As newly-launched drugs consistently fetch list prices that exceed $1 million or more, a new ICER report released Thursday finds that even the net prices ‚Äî once payer discounts are considered ‚Äî are outpacing inflation and GDP ...

- **[AstraZeneca-partnered Pinetree nears $47M Series B for protein degraders](https://endpoints.news/astrazeneca-partnered-pinetree-nears-47m-series-b-for-protein-degraders/)**  
  _Thu, 23 Oct 2025 11:00:54 +0000_  
  Pinetree Therapeutics is on the cusp of closing a $47 million Series B financing, with the goal of invigorating its pipeline following a deal with AstraZeneca last year.

 Pinetree‚Äôs raise is currently in progress and ...

- **[Roche in talks with US on drug pricing, sets out pipeline and dealmaking ambitions](https://endpoints.news/roche-in-talks-with-us-on-drug-pricing-sets-out-pipeline-and-dealmaking-ambitions/)**  
  _Thu, 23 Oct 2025 10:34:49 +0000_  
  Roche is in discussions with the US administration on drug pricing, but CEO Thomas Schinecker declined to say whether it might strike a deal similar to those recently cut by its peers Pfizer and  ...

- **[Moderna‚Äôs CMV vaccine fails Phase 3 study, will halt most development](https://endpoints.news/modernas-cmv-vaccine-fails-phase-3-study-company-to-halt-most-development/)**  
  _Wed, 22 Oct 2025 20:05:30 +0000_  
  Moderna said its cytomegalovirus vaccine failed a Phase 3 study and it will end further development of the shot for most patients.

 The company said Wednesday that the efficacy of the vaccine, called mRNA-1647, ranged ...

- **[Major pharma companies spent more on lobbying in third quarter](https://endpoints.news/major-pharma-companies-spent-more-on-lobbying-in-third-quarter/)**  
  _Wed, 22 Oct 2025 19:14:28 +0000_  
  Pfizer, Novartis, Amgen, Eli Lilly and Johnson & Johnson ‚Äî typically the top congressional lobbying spenders among the major biopharma companies ‚Äî generally spent more in the third quarter of this year than a year ago, according ...

- **[Arcturus announces mixed results of mRNA cystic fibrosis therapy, Covid-19 vaccine delay](https://endpoints.news/arcturus-announces-mixed-results-of-mrna-cystic-fibrosis-therapy-covid-19-vaccine-delay/)**  
  _Wed, 22 Oct 2025 18:39:22 +0000_  
  An ambitious attempt to restore the critical protein that is broken or missing in people with cystic fibrosis has yielded mixed results in an ongoing Phase 2 study.
 Six adults with the disease received daily ...

- **[A trio of biotechs target $250M offerings; Regeneron stops cell therapy trial](https://endpoints.news/a-trio-of-biotechs-target-250m-offerings-regeneron-stops-cell-therapy-trial/)**  
  _Wed, 22 Oct 2025 15:08:19 +0000_  
  Plus, news about AbbVie, Novartis, Analytical Biosciences, ENA Respiratory, VitriVax, Galera and Gilead:

 üëÅÔ∏è Viridian Therapeutics launches $251M offering: The biotech is selling 11.4 million shares at $22.00 apiece. It plans ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/research/2-papers-nobel-winner-debuts-technique-turn-rogue-t-cells-their-own-treatment" hreflang="en">In 2 papers, Nobel winner debuts technique to turn rogue T cells into their own treatment</a>](https://www.fiercebiotech.com/research/2-papers-nobel-winner-debuts-technique-turn-rogue-t-cells-their-own-treatment)**  
  _Oct 23, 2025 10:09am_  
  Even for a newly minted Nobel laureate, downtime is hard to find. Just a few weeks after winning the 2025 Nobel Prize in Physiology or Medicine for his discovery of regulatory T cells or Tregs, immunologist Shimon Sakaguchi, M.D., Ph.D., and colleagues have published two new papers demonstrating how rogue T cells can‚Ä¶

- **[<a href="https://www.fiercebiotech.com/biotech/ventyxs-cv-drug-reduces-stroke-biomarker-80-1st-week-phase-2-study" hreflang="en">Ventyx's CV drug reduces cardio risk biomarker by nearly 80% in 1st week of phase 2 study</a>](https://www.fiercebiotech.com/biotech/ventyxs-cv-drug-reduces-stroke-biomarker-80-1st-week-phase-2-study)**  
  _Oct 23, 2025 8:54am_  
  Ventyx Biosciences‚Äô cardiovascular disease drug cut levels of a biomarker for stroke and other serious risks by almost 80% within a week.

- **[<a href="https://www.fiercebiotech.com/medtech/china-pricing-pressure-continues-weigh-roches-diagnostics-business" hreflang="en">China pricing pressure continues to weigh on Roche's diagnostics business</a>](https://www.fiercebiotech.com/medtech/china-pricing-pressure-continues-weigh-roches-diagnostics-business)**  
  _Oct 23, 2025 4:23am_  
  Roche‚Äôs diagnostics business continues to be buffeted by China headwinds, but the Swiss major believes it has enough underlying sales strength to weather the storm.

- **[<a href="https://www.fiercebiotech.com/biotech/roche-axes-4-chugai-solid-tumor-assets-early-phase-clearout" hreflang="en">Roche axes 4 Chugai solid tumor assets in early-phase clear-out</a>](https://www.fiercebiotech.com/biotech/roche-axes-4-chugai-solid-tumor-assets-early-phase-clearout)**  
  _Oct 23, 2025 4:55am_  
  Roche has dropped five Chugai candidates from its clinical pipeline, echoing actions that the Japanese business took earlier this year.

- **[<a href="https://www.fiercebiotech.com/biotech/moderna-scraps-congenital-virus-program-after-vaccine-shows-little-protective-effect-phase" hreflang="en">Moderna scraps congenital virus program after vaccine shows little protective effect in phase 3</a>](https://www.fiercebiotech.com/biotech/moderna-scraps-congenital-virus-program-after-vaccine-shows-little-protective-effect-phase)**  
  _Oct 22, 2025 5:01pm_  
  Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women from the virus in a large phase 3 trial, the biotech announced in a post-market release.

- **[<a href="https://www.fiercebiotech.com/biotech/arcturus-stock-halves-after-mrna-therapy-fails-evoke-efficacy-cystic-fibrosis-trial" hreflang="en">Arcturus‚Äô stock halves after mRNA therapy fails to evoke efficacy in cystic fibrosis trial</a>](https://www.fiercebiotech.com/biotech/arcturus-stock-halves-after-mrna-therapy-fails-evoke-efficacy-cystic-fibrosis-trial)**  
  _Oct 22, 2025 1:03pm_  
  In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis.

- **[<a href="https://www.fiercebiotech.com/biotech/alector-nearly-halves-staff-after-gsk-partnered-antibody-flops-ph-3-dementia-trial" hreflang="en">Alector halves staff after GSK-partnered antibody flops phase 3 dementia trial</a>](https://www.fiercebiotech.com/biotech/alector-nearly-halves-staff-after-gsk-partnered-antibody-flops-ph-3-dementia-trial)**  
  _Oct 22, 2025 10:53am_  
  Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with a variety of frontotemporal dementia (FTD). To pivot away from latozinemab, the Bay Area biotech is laying off 49% of its staff, while the company‚Äôs president and head of R&D Sara Kenkare-Mitra‚Ä¶

- **[<a href="https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025" hreflang="en">Fierce Biotech Layoff Tracker 2025: Alector halves staff; Galapagos axes cell therapy unit</a>](https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025)**  
  _Dec 23, 2024 11:52am_  
  As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.

- **[<a href="https://www.fiercebiotech.com/biotech/we-need-pick-lane-lilly-oncology-president-weighs-fda-cancer-drug-policies" hreflang="en">'We need to pick a lane': Lilly oncology president weighs in on FDA cancer drug policies</a>](https://www.fiercebiotech.com/biotech/we-need-pick-lane-lilly-oncology-president-weighs-fda-cancer-drug-policies)**  
  _Oct 21, 2025 11:57am_  
  ‚ÄúWe need to pick a lane here as a country. Which one do we care more about? Proving survival, which means no crossover; or getting U.S. participation, where crossover is a pretty important incentive,‚Äù Eli Lilly‚Äôs oncology chief, Jake Van Naarden, said in an interview.


## arXiv q-bio

- **[ECKO: Explainable Clinical Knowledge for Oncology](https://arxiv.org/abs/2510.18929)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2510.18929v1 Announce Type: new 
Abstract: Personalized oncology aims to tailor treatment strategies to the unique molecular and clinical profiles of individual patients, moving beyond the traditional paradigm of treating the disease not the patient. Achieving this vision requires the integration and interpretat‚Ä¶

- **[Integrative Analysis of Epigenetic, Transcriptomic, and Metabolomic Responses to Arsenic Exposure Using Coupled Matrix Factorization](https://arxiv.org/abs/2510.19294)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2510.19294v1 Announce Type: new 
Abstract: Arsenic (As), a widespread environmental toxin, poses major health risks due to its inorganic forms (iAs), which are linked to cancer, cardiovascular disease, and endocrine disruption. Although its toxic effects have been extensively studied, the molecular mechanisms un‚Ä¶

- **[Interactive visualization of kidney micro-compartmental segmentations and associated pathomics on whole slide images](https://arxiv.org/abs/2510.19499)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2510.19499v1 Announce Type: new 
Abstract: Application of machine learning techniques enables segmentation of functional tissue units in histology whole-slide images (WSIs). We built a pipeline to apply previously validated segmentation models of kidney structures and extract quantitative features from these str‚Ä¶

- **[Prejudice driven spite: A discontinuous phase transition in ultimatum game](https://arxiv.org/abs/2510.18889)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2510.18889v1 Announce Type: cross 
Abstract: In a mix of prejudiced and unprejudiced individuals engaged in strategic interactions, the individual intensity of prejudice is expected to have effect on overall level of societal prejudice. High level of prejudice should lead to discrimination that may manifest as u‚Ä¶

- **[Category learning in deep neural networks: Information content and geometry of internal representations](https://arxiv.org/abs/2510.19021)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2510.19021v1 Announce Type: cross 
Abstract: In animals, category learning enhances discrimination between stimuli close to the category boundary. This phenomenon, called categorical perception, was also empirically observed in artificial neural networks trained on classification tasks. In previous modeling work‚Ä¶

- **[EasyVitessce: auto-magically adding interactivity to Scverse single-cell and spatial biology plots](https://arxiv.org/abs/2510.19532)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2510.19532v1 Announce Type: cross 
Abstract: EasyVitessce is a Python package that turns existing static Scanpy and SpatialData plots into interactive visualizations by virtue of adding a single line of Python code. The package uses Vitessce internally to render interactive plots, and abstracts away technical de‚Ä¶

- **[Machine Olfaction and Embedded AI Are Shaping the New Global Sensing Industry](https://arxiv.org/abs/2510.19660)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2510.19660v1 Announce Type: cross 
Abstract: Machine olfaction is rapidly emerging as a transformative capability, with applications spanning non-invasive medical diagnostics, industrial monitoring, agriculture, and security and defense. Recent advances in stabilizing mammalian olfactory receptors and integratin‚Ä¶

- **[BATIS: Bayesian Approaches for Targeted Improvement of Species Distribution Models](https://arxiv.org/abs/2510.19749)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2510.19749v1 Announce Type: cross 
Abstract: Species distribution models (SDMs), which aim to predict species occurrence based on environmental variables, are widely used to monitor and respond to biodiversity change. Recent deep learning advances for SDMs have been shown to perform well on complex and heterogen‚Ä¶

- **[Log-normal Superstatistics in the Confined Motion of Ants](https://arxiv.org/abs/1904.03236)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:1904.03236v4 Announce Type: replace 
Abstract: We report the emergence of Log-normal Superstatistics in the collective motion of ants confined in a quasi-2D arena and exposed to a panic-inducing stimulus. A data-driven superstatistical Langevin model accurately reproduces the transition from stationary behavior‚Ä¶

- **[Dynamic transitions of blind spots in the Hermann grid illusion](https://arxiv.org/abs/2408.00782)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2408.00782v2 Announce Type: replace 
Abstract: Hermann discovered the grid illusion in 1870, but its cause has remained a mystery for more than 150 years. In 1960, Baumgartner proposed a hypothesis for the illusion based on neural receptive fields, but Geier presented a counterexample in 2008. In 1995, Schrauf d‚Ä¶

- **[Interpretable Features for the Assessment of Neurodegenerative Diseases through Handwriting Analysis](https://arxiv.org/abs/2409.08303)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2409.08303v4 Announce Type: replace 
Abstract: Motor dysfunction is a common sign of neurodegenerative diseases (NDs) such as Parkinson's disease (PD) and Alzheimer's disease (AD), but may be difficult to detect, especially in the early stages. In this work, we examine the behavior of a wide array of interpretab‚Ä¶

- **[Comorbid anxiety predicts lower odds of MDD improvement in a trial of smartphone-delivered interventions](https://arxiv.org/abs/2409.11183)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2409.11183v4 Announce Type: replace 
Abstract: Comorbid anxiety disorders are common among patients with major depressive disorder (MDD), but their impact on outcomes of digital and smartphone-delivered interventions is not well understood. This study is a secondary analysis of a randomized controlled effectiven‚Ä¶

- **[A Comprehensive Benchmark for RNA 3D Structure-Function Modeling](https://arxiv.org/abs/2503.21681)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2503.21681v3 Announce Type: replace 
Abstract: The relationship between RNA structure and function has recently attracted interest within the deep learning community, a trend expected to intensify as nucleic acid structure models advance. Despite this momentum, the lack of standardized, accessible benchmarks for‚Ä¶

- **[Lineage topology, replication kinetics and cell cycle synchronization reveal regulated growth dynamics in human bone marrow stromal cell colonies](https://arxiv.org/abs/2504.21818)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2504.21818v2 Announce Type: replace 
Abstract: Bone marrow stromal cells (BMSC) -- which include skeletal stem cells -- are a promising tool in regenerative medicine. However, their heterogeneous and unpredictable in vivo behaviour remains a critical barrier preventing the development of standardized therapeutic‚Ä¶

- **[Decomposing stimulus-specific sensory neural information via diffusion models](https://arxiv.org/abs/2505.11309)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2505.11309v2 Announce Type: replace 
Abstract: To understand sensory coding, we must ask not only how much information neurons encode, but also what that information is about. This requires decomposing mutual information into contributions from individual stimuli and stimulus features: a fundamentally ill-posed‚Ä¶

- **[CNeuroMod-THINGS, a densely-sampled fMRI dataset for visual neuroscience](https://arxiv.org/abs/2507.09024)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2507.09024v4 Announce Type: replace 
Abstract: Data-hungry neuro-AI modelling requires ever larger neuroimaging datasets. CNeuroMod-THINGS meets this need by capturing neural representations for a wide set of semantic concepts using well-characterized images in a new densely-sampled, large-scale fMRI dataset. Im‚Ä¶

- **[Saccade crossing avoidance as a visual search strategy](https://arxiv.org/abs/2508.18404)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2508.18404v2 Announce Type: replace 
Abstract: Although visual search appears largely random, several oculomotor biases exist such that the likelihoods of saccade directions and lengths depend on the previous scan path. Compared to the most recent fixations, the impact of the longer path history is more difficul‚Ä¶

- **[Intelligent Software System for Low-Cost, Brightfield Segmentation: Algorithmic Implementation for Cytometric Auto-Analysis](https://arxiv.org/abs/2509.11354)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2509.11354v4 Announce Type: replace 
Abstract: Bright-field microscopy, a cost-effective solution for live-cell culture, is often the only resource available, along with standard CPUs, for many low-budget labs. The inherent chal- lenges of bright-field images - their noisiness, low contrast, and dynamic morpholo‚Ä¶

- **[AtomSurf : Surface Representation for Learning on Protein Structures](https://arxiv.org/abs/2309.16519)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2309.16519v4 Announce Type: replace-cross 
Abstract: While there has been significant progress in evaluating and comparing different representations for learning on protein data, the role of surface-based learning approaches remains not well-understood. In particular, there is a lack of direct and fair benchmark‚Ä¶

- **[LICO: Large Language Models for In-Context Molecular Optimization](https://arxiv.org/abs/2406.18851)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2406.18851v2 Announce Type: replace-cross 
Abstract: Optimizing black-box functions is a fundamental problem in science and engineering. To solve this problem, many approaches learn a surrogate function that estimates the underlying objective from limited historical evaluations. Large Language Models (LLMs), wit‚Ä¶

- **[ScholaWrite: A Dataset of End-to-End Scholarly Writing Process](https://arxiv.org/abs/2502.02904)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2502.02904v4 Announce Type: replace-cross 
Abstract: Writing is a cognitively demanding activity that requires constant decision-making, heavy reliance on working memory, and frequent shifts between tasks of different goals. To build writing assistants that truly align with writers' cognition, we must capture an‚Ä¶

- **[PRING: Rethinking Protein-Protein Interaction Prediction from Pairs to Graphs](https://arxiv.org/abs/2507.05101)**  
  _Thu, 23 Oct 2025 00:00:00 -0400_  
  arXiv:2507.05101v2 Announce Type: replace-cross 
Abstract: Deep learning-based computational methods have achieved promising results in predicting protein-protein interactions (PPIs). However, existing benchmarks predominantly focus on isolated pairwise evaluations, overlooking a model's capability to reconstruct biol‚Ä¶
